All Stories

  1. Psychosocial mediators of the relations between sexual orientation and depressive symptoms in a longitudinal sample of young people.
  2. Telephone delivered incentives for encouraging adherence to supervised methadone consumption (TIES): Study protocol for a feasibility study for an RCT of clinical and cost effectiveness
  3. The Genetic Links to Anxiety and Depression (GLAD) Study: Online recruitment into the largest recontactable study of depression and anxiety
  4. Cognitive behavioural therapy for irritable bowel syndrome: 24-month follow-up of participants in the ACTIB randomised trial
  5. A genome-wide association meta-analysis of prognostic outcomes following cognitive behavioural therapy in individuals with anxiety and depressive disorders
  6. Assessing telephone-delivered cognitive–behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial
  7. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT
  8. Childhood gender‐typed behavior and emotional or peer problems: a prospective birth‐cohort study
  9. The PACE trial of treatments for chronic fatigue syndrome: a response to WILSHIRE et al
  10. Key mechanisms of cognitive behavioural therapy in irritable bowel syndrome: The importance of gastrointestinal related cognitions, behaviours and general anxiety
  11. Cognitive and Behavioral Differences Between Subtypes in Refractory Irritable Bowel Syndrome
  12. Blinding participants and assessors in a feasibility randomised controlled trial of peer-befriending for people with aphasia post-stroke
  13. How can we figure out how treatments work?
  14. The importance of cluster analysis for enhancing clinical practice: an example from irritable bowel syndrome
  15. Psychometric properties and factor structure of a shortened version of the Cognitive Behavioural Responses Questionnaire (CBRQ)
  16. Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study)
  17. The journey between brain and gut: A systematic review of psychological mechanisms of treatment effect in irritable bowel syndrome
  18. Guided Self-Help for Patients with Chronic Fatigue Syndrome Prior to Starting Cognitive Behavioural Therapy: a Cohort Study
  19. Response to the editorial by Dr Geraghty
  20. Do more people recover from chronic fatigue syndrome with cognitive behaviour therapy or graded exercise therapy than with other treatments?
  21. The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder
  22. Measurement error, time lag, unmeasured confounding: Considerations for longitudinal estimation of the effect of a mediator in randomised clinical trials
  23. Cognitive behaviour therapy for chronic fatigue syndrome: Differences in treatment outcome between a tertiary treatment centre in the United Kingdom and the Netherlands
  24. Patient reaction to the PACE trial – Authors' reply
  25. Establishing how psychological therapies work: the importance of mediation analysis
  26. Rehabilitative treatments for chronic fatigue syndrome: long-term follow-up from the PACE trial
  27. Methods and outcome reporting in the PACE trial–Author's reply
  28. Rehabilitative therapies for chronic fatigue syndrome: a secondary mediation analysis of the PACE trial
  29. Adverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome
  30. One-day cognitive-behavioural therapy self-confidence workshops for people with depression: randomised controlled trial
  31. PACE trial authors' reply to letter by Kindlon
  32. Letter to the Editor: Response to correspondence concerning ‘Recovery from chronic fatigue syndrome after treatments in the PACE trial’
  33. Recovery from chronic fatigue syndrome after treatments given in the PACE trial
  34. A randomised trial of adaptive pacing therapy, cognitive behaviour therapy, graded exercise, and specialist medical care for chronic fatigue syndrome (PACE): statistical analysis plan
  35. Adaptive Pacing, Cognitive Behaviour Therapy, Graded Exercise, and Specialist Medical Care for Chronic Fatigue Syndrome: A Cost-Effectiveness Analysis
  36. Prolonged Stay in Intensive Care Unit Is a Powerful Predictor of Adverse Outcomes After Cardiac Operations
  37. Department of Error
  38. The PACE trial in chronic fatigue syndrome – Authors' reply
  39. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial
  40. Collaborative community based care for people and their families living with schizophrenia in India: protocol for a randomised controlled trial
  41. Comparison of Outcomes From Smoking and Nonsmoking Donors: Thirteen-Year Experience
  42. Microsimulation and clinical outcomes analysis support a lower age threshold for use of biological valves
  43. A lipopolysaccharide adsorber in adult cardiopulmonary bypass: a single centre randomised controlled pilot trial
  44. A Valuation of Infusion Therapy to Preserve Islet Function in Type 1 Diabetes
  45. Mapping of the EQ-5D index from clinical outcome measures and demographic variables in patients with coronary heart disease
  46. A review of health utilities using the EQ-5D in studies of cardiovascular disease
  47. Aspiration and development of subglottic stenosis in patients with Wegener’s granulomatosis
  48. Connective Tissue Disease–associated Pulmonary Arterial Hypertension in the Modern Treatment Era
  49. Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions
  50. Life-Years Gained by Reducing Donor Heart Ischemic Times
  51. The influence of seasonal variation on cardiac surgery: A time-related clinical outcome predictor
  52. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension
  53. Current differences in referral patterns for pulmonary endarterectomy in the UK
  54. Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension
  55. What affected survival of Papworth Hospital heart transplantation patients over the first 25 years?
  56. Impact of Cardiothoracic Resident Turnover on Mortality After Cardiac Surgery: A Dynamic Human Factor
  57. Clinical and cost-effectiveness analysis of an open label, single-centre, randomised trial of spinal cord stimulation (SCS) versus percutaneous myocardial laser revascularisation (PMR) in patients with refractory angina pectoris: The SPiRiT trial
  58. The Papworth BiVent tube: a new device for lung isolation
  59. Improved Outcomes in Medically and Surgically Treated Chronic Thromboembolic Pulmonary Hypertension
  60. Does perioperative use of aprotinin reduce the rejection rate in heart transplant recipients?☆
  61. Fibrinogen A  Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension
  62. Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension
  63. Reply to Yavuz et al.
  64. Unintended Childbearing and Knowledge of Emergency Contraception in a Population-Based Survey of Postpartum Women
  65. Unintended Childbearing and Knowledge of Emergency Contraception in a Population-Based Survey of Postpartum Women
  66. A surgeon's case volume of oesophagectomy for cancer strongly influences the operative mortality rate
  67. Report of the Specialist Advisory Committee on Antimicrobial Resistance (SACAR) Surveillance Subgroup
  68. Right Ventricular Septal Pacing
  69. Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH)
  70. Delayed re-exploration for bleeding after coronary artery bypass surgery results in adverse outcomes☆
  71. An Assessment of Web Accessibility Knowledge and Needs at Oregon Community Colleges
  72. The Extracellular Domain of Herpes Simplex Virus gE Is Indispensable for Efficient Cell-to-Cell Spread: Evidence for gE/gI Receptors
  73. Herpes Simplex Virus Glycoproteins gD and gE/gI Serve Essential but Redundant Functions during Acquisition of the Virion Envelope in the Cytoplasm
  74. Herpes Simplex Virus with Highly Reduced gD Levels Can Efficiently Enter and Spread between Human Keratinocytes
  75. Infected Cell Protein (ICP)47 Enhances Herpes Simplex Virus Neurovirulence by Blocking the CD8+T Cell Response